Table of Contents
1 Executive Summary
- 1.1 Introduction
- 1.2 Scope and Methodology
- 1.3 Size and Growth of the Market
2 Introduction
- 2.1 History and Growth of the Cancer Treatment Market: Monoclonal Antibody Discovery
- 2.2 The Role of Biotechnology in Cancer Treatment
- 2.3 Monoclonal Antibody Technology
- 2.4 Industry Structure
- 2.5 Demographics and Statistics
3 Current Monoclonal Antibodies for Cancer Treatment
- 3.1 Overview
- 3.1.1 Description of Cancers with Available Products
- 3.1.1.1 Breast Cancer
- 3.1.1.2 Non-Hodgkinfs Lymphoma
- 3.2 Description of Products
- 3.2.1 Bexxar
- 3.2.2 Herceptin
- 3.2.3 Rituxan
- 3.2.4 Zevalin
- 3.3 Market Size and Growth
- 3.4 Competitive Analysis
4 Emerging Monoclonal Antibodies for Cancer Treatment
- 4.1 Overview
- 4.1.1 Description of Cancers with New Product Opportunities
- 4.1.1.1 Colon Cancer
- 4.1.1.2 Head/Neck Cancer
- 4.1.1.3 Leukemia
- 4.1.1.4 Lung Cancer
- 4.1.1.5 Melanoma
- 4.1.1.6 Multiple Myeloma
- 4.1.1.7 Ovarian Cancer
- 4.1.1.8 Pancreatic Cancer
- 4.1.1.9 Prostate Cancer
- 4.1.1.10 Stomach Cancer
- 4.1.1.11 Other Cancers
- 4.2 Monoclonal Antibody Pipeline (Cancer)
- 4.2.1 Phase III
- 4.2.2 Phase II
- 4.2.3 Phase I
- 4.2.4 Pre-clinical
- 4.3 Market and Product Launch Forecasts
- 4.4 Potential Competitors and Analysis, 2008
5 Issues and Trends Affecting the Monoclonal Antibody Market
- 5.1 Introduction
- 5.2 Insurance and Reimbursement Issues
- 5.3 Global Issues
- 5.4 Strategic Trends and Issues
- 5.5 Treatment Costs
- 5.6 Alliances, Acquisitions and Licensing Agreements
- 5.7 Marketing and Distribution Trends
- 5.8 Manufacturing Issues
- 5.9 Diagnostic Applications of Monoclonal Antibodies, an Overview
6 Total Market Size and Forecast
- 6.1 Overview
- 6.2 Total Market Size and Forecast
- 6.3 Competitor Analysis
- 6.4 Market Analysis
7 Corporate Profiles for Current Developers/Providers of Monoclonal Antibodies for Cancer Treatment
- 7.1 Introduction
- 7.2 Biogen IDEC
- 7.3 Corixa Corporation
- 7.4 Genentech
- 7.5 GlaxoSmithKline
8 Company Profiles for the Emerging Monoclonal Antibody Cancer Treatment Market
- 8.1 Introduction
- 8.2 Abgenix
- 8.3 Amgen
- 8.4 Bristol-Myers
- 8.5 CellTech
- 8.6 ILEX Oncology
- 8.7 Imclone Systems
- 8.8 ImmunoGen
- 8.9 Immunomedics
- 8.10 MedImmune
- 8.11 Merck & Company
- 8.12 Peregrine Pharmaceuticals
- 8.13 Protein Design Labs
- 8.14 Unither Pharmaceuticals
- 8.15 Wyeth
9 Appendix: Company Names and Addresses |
Related Report
|
View Cart
